Biotech · Private company · Richmond, VA, US
Illexcor Therapeutics, LLC
Track this companyFree. Adds Illexcor Therapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards4
- Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease TherapyFiscal year 2025 · $529.3KNIH RePORTER 5R44HL154864-04 · fetched Nov 12, 2026
- Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifierFiscal year 2025 · $798.4KNIH RePORTER 5R44HL156334-04 · fetched Nov 12, 2026
- Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease TherapyFiscal year 2024 · $887.9KNIH RePORTER 5R44HL154864-03 · fetched Nov 12, 2026
- Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifierFiscal year 2024 · $807.8KNIH RePORTER 5R44HL156334-03 · fetched Nov 12, 2026